Johnson & Johnson: ICOTYDE drug shows sustained efficacy in plaque psoriasis over two years

Johnson & Johnson has announced new two-year data from the Phase 3 ICONIC-TOTALa study, highlighting the sustained efficacy of its plaque psoriasis treatment, ICOTYDE® (icotrokinra). The study focused on patients with psoriasis affecting high-impact areas such as the scalp, genitals, hands, and feet.

The data, presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026, indicate that ICOTYDE, a targeted oral peptide blocking the IL-23 receptor, maintained significant skin clearance in adult and adolescent patients through Week 112. This marks a critical update on its long-term performance.

Key findings include high rates of site-specific complete skin clearance. Specifically, 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved complete clearance in those affected areas. Improvements were also noted in nail psoriasis.

Johnson & Johnson stated that these results affirm ICOTYDE's role as a potent first-line systemic therapy, offering enduring clinical outcomes for patients dealing with psoriasis in challenging body locations where topical treatments may be less effective. The safety profile remained consistent with previously established data.